|
Ten Generic Makers Ready to Pounce on Merck’s Blockbuster Singulair
The FDA has approved a slew of generic drug applications for Merck’s asthma and allergy drug Singulair as the blockbuster drug succumbs to patent expiry and its loss of pediatric marketing exclusivity.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives